CRBU - Caribou stock pops on FDA fast track tag for blood cancer therapy CB-011

2023-04-04 08:58:11 ET

• The U.S. Food and Drug Administration (FDA) granted fast track designation to Caribou Biosciences' ( NASDAQ: CRBU ) allogeneic CAR-T cell therapy CB-011 to treat relapsed or refractory multiple myeloma (r/r MM).
• CB-011 is being evaluated in a phase 1 trial, dubbed CaMMouflage, in patients with r/r MM, a type of blood cancer.
• "Our goal is to develop CB-011 as a readily available off-the-shelf treatment option for patients with relapsed or refractory multiple myeloma to overcome the need for apheresis or bridging therapy, variable quality and long manufacturing timelines, manufacturing failures, or the inability to bear the burden of treatments that require frequent dosing over several months," said Caribou's Chief Medical Officer Syed Rizvi.
• CRBU +4.02% to $5.69 premarket April 4

For further details see: